EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.